Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Inclusion Criteria

• •Diagnosis and Main Criteria for Inclusion/Exclusion:
• •Main Study - patients with MSS mCRC These criteria are applicable for both Dose Escalation and Expansion part of the Main Study; criteria specific for each study part are identified with ESC=Escalation or EXP=Expansion.
• •1. Signed and dated informed consent obtained before undergoing any study-specific procedure
• •2. Male or female aged ≥18 years
• •3. ESC - Histologically confirmed diagnosis of adenocarcinoma originating from the colon or rectum, with known RAS and BRAF mutational status as assessed per standard practice.
• •EXP - Histologically confirmed diagnosis of adenocarcinoma originating from the colon or rectum, with known RAS and BRAF mutational status as assessed per standard practice.
• •For patients included in the Expansion part only: PD-L1 CPS or adequate tissue to perform PD-L1 CPS assessment should be available.
• •4. Stage IV (according to the American Joint Committee on Cancer definition)
• •5. Presence of measurable disease per RECIST v1.1 (based on imaging within 28 days from first study drug administration). Patients must have at least one "target lesion" to be used to assess response, as defined by RECIST v1.1 Note: Subjects with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately
• •6. ESC - Disease progression after at least two standard treatment lines for mCRC, including fluoropyrimidines, oxaliplatin and irinotecan and, if RAS and BRAF wild-type, cetuximab or panitumumab or, intolerance or refusal of chemotherapy regimens for mCRC Note: Previous oxaliplatin-based adjuvant treatment is considered as a treatment line if disease relapse occurred within 6 months from its completion
• •EXP - Disease progression after at least two standard treatment lines for mCRC, including fluoropyrimidines, oxaliplatin and irinotecan and:
• •1. if RAS and BRAF wild type, cetuximab or panitumumab
• •2. if BRAFV600E mutated encorafenib and cetuximab or intolerance or refusal of chemotherapy regimens for mCRC. Note: Previous oxaliplatin-based adjuvant treatment is considered as a treatment line if disease relapse occurred within 6 months from its completion 7. Naïve to any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints inhibitors) and EP4 receptor antagonists 8. ESC - Availability of adequate and sufficient baseline tumour tissue sample (archival or newly obtained biopsy) Note: an adequate and sufficient sample is defined as formalin fixed paraffin embedded tumour tissue sample, preferably from the most recent biopsy of a tumour lesion, collected either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated. If no tumour tissue is available, a fresh tissue from needle or excisional biopsy or from resection is required EXP - Availability of adequate and sufficient newly obtained fresh tumour tissue sample collected after ICF during the screening period and before the treatment starts. In case the biopsy collection is not feasible, according to Investigator judgement or patient decision, archival biopsy or surgical sample can be accepted after discussion with the Sponsor.
• •Note: an adequate and sufficient sample is defined as formalin fixed paraffin embedded tumour tissue sample, collected from a site not previously irradiated. If the formalin fixed paraffin embedded tumor tissue sample obtained after the last treatment line and 90 days before the ICF signature, the patient is considered eligible, If the fresh tissue from needle or excisional biopsy/resection is not feasible according to the Investigator judgement, the patients may be eligible after discussion with the Sponsor.
• •9\. pMMR/MSS defined as CRC with all 4 MMR proteins intact and/or with instability at ≤1/5 locus (or 30% of loci if larger panel of markers are assayed) 10. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 11. Anticipated life expectancy ≥ 3 months 12. Adequate hematologic and end organ function, defined by the following laboratory results, obtained within 7 days before first dose of study drug treatment:
• •1. Hemoglobin ≥ 10 g/dL, platelet count ≥100,000/mm3, ANC ≥1500/mm3
• •2. Creatinine clearance ≥ 50 mL/min
• •3. Amylase and lipase ≤ 1.5 × ULN
• •4. Serum bilirubin ≤ 1.5× ULN
• •5. AST, ALT, and ALP ≤ 2.5 × ULN with the following exceptions:
• •* Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN
• •6. INR and PTT ≤ 1.5 × ULN.
• •* Patients who are on therapeutic doses of anti-coagulants should be on a stable dose for 28 days, with stable INR and PTT values.
• •7. Serum albumin ≥ 3.0 g/dL
• •13\. Ability e and willingness to participate and comply with the requirements of the entire study
• •Study Extension - other metastatic GI cancers Cohorts A and B - Gastric cancer
• •1. Signed and dated informed consent obtained before undergoing any study-specific procedure
• •2. Male or female aged ≥18 years
• •3. Body weight \> 40kg
• •4. Histologically proven advanced-stage unresectable adenocarcinoma of the stomach or the GEJ
• •5. Stage IV (according to the American Joint Committee on Cancer definition)
• •6. Available CPS or available tissue to perform CPS assessment: Cohort A: CPS≥5 - Cohort B CPS\<5
• •7. Failure to at least one prior line of chemotherapy for metastatic disease, given with or without trastuzumab, with or without anti-PD-1. In alternative, early disease recurrence after surgery with neo-adjuvant and/or adjuvant chemotherapy (within 6 months of the last administration of chemotherapy) or progression during neo-adjuvant and/or adjuvant chemotherapy (containing fluoropyrimidine and a platinum derivative).
• •8. Presence of measurable disease per RECIST v1.1 (based on imaging within 28 days from first study drug administration). Patients must have at least one "target lesion" to be used to assess response, as defined by RECIST v1.1 Note: Subjects with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately
• •9. Naïve to EP4 receptor antagonists
• •10. Availability of adequate and sufficient baseline tumour tissue sample (archival or newly obtained biopsy) Note: an adequate and sufficient sample is defined as formalin fixed paraffin embedded tumour tissue sample, preferably from the most recent biopsy of a tumour lesion, collected either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated. If no tumour tissue is available, a fresh tissue from needle or excisional biopsy or from resection is required
• •11. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
• •12. Anticipated life expectancy ≥ 3 months
• •13. Adequate hematologic and end organ function, defined by the following laboratory results, obtained within 7 days before first dose of study drug treatment:
• •<!-- -->
• •1. Hemoglobin ≥ 10 g/dL, platelet count ≥100,000/mm3, ANC ≥1500/mm3
• •2. Creatinine clearance ≥ 50 mL/min
• •3. Amylase and lipase ≤ 1.5 × ULN
• •4. Serum bilirubin ≤ 1.5× ULN
• •5. AST, ALT, and ALP ≤ 2.5 × ULN with the following exceptions:
• •* Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN
• •6. INR and PTT ≤ 1.5 × ULN.
• •* Patients who are on therapeutic doses of anti-coagulants should be on a stable dose for 28 days, with stable INR and PTT values.
• •7. Serum albumin ≥ 3.0 g/dL
• •14\. Ability e and willingness to participate and comply with the requirements of the entire study
• •Cohort C - GI cancers other than CRC and GC
• •1. Signed and dated informed consent obtained before undergoing any study-specific procedure
• •2. Male or female aged ≥18 years
• •3. Body weight \> 40kg
• •4. Histologically proven advanced-stage unresectable GI cancer other than CRC and GC
• •5. Stage IV (according to the American Joint Committee on Cancer definition)
• •6. Failure to at least one prior line of chemotherapy for metastatic disease, given with or without trastuzumab, with or without anti-PD-1. In alternative, early disease recurrence after surgery with neo-adjuvant and/or adjuvant chemotherapy (within 6 months of the last administration of chemotherapy) or progression during neo-adjuvant and/or adjuvant chemotherapy (containing fluoropyrimidine and a platinum derivative).
• •7. Presence of measurable disease per RECIST v1.1 (based on imaging within 28 days from first study drug administration). Patients must have at least one "target lesion" to be used to assess response, as defined by RECIST v1.1 Note: Subjects with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately
• •8. Naïve to EP4 receptor antagonists
• •9. Availability of adequate and sufficient baseline tumour tissue sample (archival or newly obtained biopsy) Note: an adequate and sufficient sample is defined as formalin fixed paraffin embedded tumour tissue sample, preferably from the most recent biopsy of a tumour lesion, collected either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated. If no tumour tissue is available, a fresh tissue from needle or excisional biopsy or from resection is required
• •10. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
• •11. Anticipated life expectancy ≥ 3 months
• •12. Adequate hematologic and end organ function, defined by the following laboratory results, obtained within 7 days before first dose of study drug treatment:
• •<!-- -->
• •1. Hemoglobin ≥ 10 g/dL, platelet count ≥100,000/mm3, ANC ≥1500/mm3
• •2. Creatinine clearance ≥ 50 mL/min
• •3. Amylase and lipase ≤ 1.5 × ULN
• •4. Serum bilirubin ≤ 1.5× ULN
• •5. AST, ALT, and ALP ≤ 2.5 × ULN with the following exceptions:
• •* Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN
• •6. INR and PTT ≤ 1.5 × ULN.
• •* Patients who are on therapeutic doses of anti-coagulants should be on a stable dose for 28 days, with stable INR and PTT values.
• •7. Serum albumin ≥ 3.0 g/dL
• •13\. Ability e and willingness to participate and comply with the requirements of the entire study
• •3. Major surgery within 28 days before Cycle 1 Day 1 or anticipation of needing such procedure during the trial
• •4. Treatment with any systemic or localized anti-cancer therapy, including chemotherapy, biological therapy, radiotherapy, or hormonal therapy within 28 days before initiation of Cycle 1 Day 1 or expected to require such a treatment during the trial
• •5. Persistent toxicity related to prior therapy, Grade \>1 according to NCI CTCAE Version 5.0 Note 1: Patients must have recovered from all AEs due to previous therapies, to CTCAE ≤Grade 1 or to baseline condition. Participants with CTCAE ≤Grade 2 neuropathy or alopecia may be eligible Note 2: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment Note 3: Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
• •6. Uncontrolled tumour-related pain. Patients requiring narcotic pain medication must be on a stable regimen at study entry
• •7. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage more than once every 28 days. Indwelling drainage catheters are allowed
• •Cardiovascular:
• •8. Unstable angina
• •9. Myocardial infarction within 6 months before enrolment
• •10. History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 6 months before enrolment
• •11. Uncontrolled ventricular arrhythmia
• •12. Congestive heart failure (New York Hearth Association class ≥II)
• •13. Poorly controlled hypertension
• •Infections:
• •14. Confirmed infection with SARS-CoV-2 as documented by molecular testing at nasopharyngeal swab (only if required by the epidemiological situation)
• •15. HIV infection
• •16. Active tuberculosis
• •17. Acute or chronic viral hepatitis B or C infection
• •18. Any severe infection within 14 days before Cycle 1 Day 1
• •General Medical History:
• •19. Active autoimmune disease in the past 2 years
• •20. History of allogenic tissue/solid organ transplant (including allogeneic bone marrow transplantation)
• •21. History of immunodeficiency
• •22. History or presence of interstitial lung disease or history of pneumonitis that has required oral or iv corticosteroids.
• •23. History of gastric/duodenal ulcers, colitis and/or gastrointestinal bleeding
• •24. History of severe gastrointestinal adverse reactions
• •25. History of hypersensitivity reactions to fully human monoclonal antibodies, Grade ≥ 3 according to NCI CTCAE Version 5.0
• •26. History of anaphylaxis, or uncontrolled asthma
• •27. Allergy/hypersensitivity/intolerance to any component of CR6086 or AGEN2034
• •28. Any other clinically relevant disease and condition, including psychiatric or substance abuse disorders, that, in the opinion of the Investigator, may jeopardize efficacy or safety assessments, confound the result of the trial or may compromise the patient's safety during trial participation
• •Concomitant Treatments
• •29. Administration of a live, attenuated vaccine within 28 days before Cycle 1 D1
• •30. Systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before screening Note: Corticosteroid use for management of immune-related adverse events, and/or as a premedication for iv contrast allergies/reactions is allowed.
• •Daily corticosteroid replacement therapy is allowed: permitted therapy are daily prednisone at doses of 5 to 7.5 mg or equivalent hydrocortisone dose, and steroid therapy administered by topical, intraocular, intranasal, and/or inhalation routes
• •31. Regular use of any illicit drugs or recent history (within the last year) of substance abuse (including alcohol)
• •Others:
• •32. Participation in a study with an investigational drug or medical device within 28 days before Cycle 1 Day 1 Note: Participants who have entered the follow-up phase of another investigational study may participate as long as at least 4 weeks have elapsed since the last dose of the investigational agent
• •33. Inability to swallow medications
• •34. Malabsorption conditions
• •35. For women of childbearing potential:
• •* Pregnancy (i.e. positive pregnancy test at Screening) or breastfeeding
• •* Failure to agree to practice a highly effective method of contraception , from enrolment up to at least 120 days after the last IMP intake
• •* expecting to conceive within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of study treatment
• •36. For sexually active men with a female partner of childbearing potential: failure to agree to use condom and refrain from donating sperm from enrolment up to at least 120 days after the last IMP intake.
• •37. Patients who are legally incapacitated or has limited legal capacity
• •Criteria for Study Extension only
• •38. Presence of portal hypertension
• •39. Presence of oesophageal varices
• •40. Presence of gastric infiltration, severe gastritis, duodenal or gastric ulcer, or any other condition that may lead to bleeding or perforation, as assessed by an EGDS performed during screening period.
• •Criteria referring to Cycle 1 D1, should be reassessed on study D1, before starting the study treatment.